Related references
Note: Only part of the references are listed.Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection
Amandine Landemaine et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy
Eugenia Santacana Juncosa et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy
Adam S. Darwich et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021 (2021)
Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience
Mihika B. Dave et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
Ana-Marija Grisic et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
Anne S. Strik et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2021)
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases
Wannee Kantasiripitak et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection
Alexander Eser et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease
Laura E. Bauman et al.
INFLAMMATORY BOWEL DISEASES (2020)
Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design
Eugenia Santacana et al.
THERAPEUTIC DRUG MONITORING (2020)
Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics
Katsuyoshi Matsuoka et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2020)
DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
E Dreesen et al.
Journal of Crohns & Colitis (2020)
Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
Gyeol Seong et al.
MICROORGANISMS (2020)
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease
Sine Buhl et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2020)
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients
Mayte Gil Candel et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2020)
Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data
Joao A. Abrantes et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases
Antoine Petitcollin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Optimising infliximab induction dosing for patients with ulcerative colitis
Erwin Dreesen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy
Yizhong Wang et al.
JOURNAL OF CROHNS & COLITIS (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease
Amy Hemperly et al.
CLINICAL PHARMACOKINETICS (2018)
Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment
Erwin Dreesen et al.
CURRENT DRUG TARGETS (2018)
Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study
Antoine Petitcollin et al.
INFLAMMATORY BOWEL DISEASES (2018)
Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System
Alexander Eser et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis
David Kevans et al.
JOURNAL OF CROHNS & COLITIS (2018)
Measures of Model Performance Based On the Log Accuracy Ratio
S. K. Morley et al.
SPACE WEATHER-THE INTERNATIONAL JOURNAL OF RESEARCH AND APPLICATIONS (2018)
Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration
Helena Edlund et al.
AAPS JOURNAL (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
Johannan F. Brandse et al.
INFLAMMATORY BOWEL DISEASES (2017)
Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease
Adam Frymoyer et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
External Evaluation Of Population Pharmacokinetic Models Of Infliximab In Inflammatory Bowel Disease Patients
Eugènia Santacana et al.
THERAPEUTIC DRUG MONITORING (2017)
Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact
Daniel Gonzalez et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies
Jessica Wojciechowski et al.
AAPS JOURNAL (2017)
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A. S. Darwich et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling
Esther J. H. Janssen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
Johannan F. Brandse et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition
Maria K. Magnusson et al.
JOURNAL OF CROHNS & COLITIS (2016)
Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease
Adam Frymoyer et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2016)
The underlying inflammatory chronic disease influences infliximab pharmacokinetics
Christophe Passot et al.
MABS (2016)
Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software
Michael Neely et al.
THERAPEUTIC DRUG MONITORING (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice
D. J. Buurman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice
A. Smits et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease
Alexandre Aubourg et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2015)
Dashboard Systems: Pharmacokinetic/Pharmacodynamic Mediated Dose Optimization for Monoclonal Antibodies
Diane R. Mould et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients
Eugènia Santacana Juncosa et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2015)
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease
David Ternant et al.
CLINICAL PHARMACOKINETICS (2015)
The challenge of indication extrapolation for infliximab biosimilars
Brian G. Feagan et al.
BIOLOGICALS (2014)
Evidence-Based Morphine Dosing for Postoperative Neonates and Infants
Elke H. J. Krekels et al.
CLINICAL PHARMACOKINETICS (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings
Wei Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Narendra Chirmule et al.
AAPS JOURNAL (2012)
Monitoring drug therapy
Thierry Buclin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis
Lennard Y. W. Lee et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models
Xu Steven Xu et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2011)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients
David Ternant et al.
THERAPEUTIC DRUG MONITORING (2009)
Clinical pharmacokinetics and use of infliximab
Ulrich Klotz et al.
CLINICAL PHARMACOKINETICS (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
Perls-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2004)
Share Paper
